TWI790573B - 白介素2突變體及其用途 - Google Patents
白介素2突變體及其用途 Download PDFInfo
- Publication number
- TWI790573B TWI790573B TW110110014A TW110110014A TWI790573B TW I790573 B TWI790573 B TW I790573B TW 110110014 A TW110110014 A TW 110110014A TW 110110014 A TW110110014 A TW 110110014A TW I790573 B TWI790573 B TW I790573B
- Authority
- TW
- Taiwan
- Prior art keywords
- mutation
- mutein
- cells
- protein
- sequence
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010197740.4 | 2020-03-19 | ||
| CN202010197740 | 2020-03-19 | ||
| CN202110266549.5 | 2021-03-11 | ||
| CN202110266549 | 2021-03-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202144392A TW202144392A (zh) | 2021-12-01 |
| TWI790573B true TWI790573B (zh) | 2023-01-21 |
Family
ID=77770497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110110014A TWI790573B (zh) | 2020-03-19 | 2021-03-19 | 白介素2突變體及其用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230145766A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4122952A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7879043B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220155316A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115698052A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021239225B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3175717A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI790573B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021185361A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| CN112105634B (zh) | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| WO2021185362A1 (zh) * | 2020-03-19 | 2021-09-23 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
| CN118598977A (zh) * | 2020-10-18 | 2024-09-06 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TWI825544B (zh) | 2020-12-31 | 2023-12-11 | 大陸商信達生物製藥(蘇州)有限公司 | 含異二聚體抗體Fc的蛋白以及其製備方法 |
| JP7864826B2 (ja) * | 2021-09-22 | 2026-05-25 | フォートビタ バイオロジクス(シンガポール)プライベート リミティド | インターロイキン2変異体およびその融合タンパク質 |
| CN116375879A (zh) * | 2021-12-16 | 2023-07-04 | 信达生物制药(苏州)有限公司 | B7-h3免疫缀合物及其应用 |
| WO2023169524A1 (zh) * | 2022-03-10 | 2023-09-14 | 广东菲鹏制药股份有限公司 | 白细胞介素2突变体以及含有其的复合物 |
| IL317511A (en) | 2022-06-16 | 2025-02-01 | Cephalon Llc | IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses |
| WO2023241653A1 (zh) * | 2022-06-17 | 2023-12-21 | 舒泰神(北京)生物制药股份有限公司 | 白介素-2(il-2)突变体及其用途 |
| WO2024008126A1 (en) * | 2022-07-06 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Il2 muteins and uses thereof |
| CN118620056A (zh) * | 2023-03-09 | 2024-09-10 | 北京天广实生物技术股份有限公司 | Il-2变体及其用途 |
| KR20260008731A (ko) * | 2023-03-21 | 2026-01-16 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 항-pd-1 및 돌연변이 il-2 면역접합체 제제 |
| EP4739334A1 (en) * | 2023-07-05 | 2026-05-13 | Nanotein Technologies, Inc. | Cell signaling complexes and uses thereof |
| CN117116336B (zh) * | 2023-10-18 | 2024-01-23 | 深圳新锐基因科技有限公司 | 基于内部原子波动改善蛋白结构柔性弱点的方法和装置 |
| IL328822A (en) * | 2023-12-19 | 2026-08-01 | Cephalon Llc | Uses for attenuated IL-2 immunosuppressants |
| WO2026012466A1 (en) * | 2024-07-12 | 2026-01-15 | Vibrant Pharma Limited | Interleukin-2 muteins and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002000A1 (en) * | 1989-08-02 | 1991-02-21 | Seragen, Inc. | Il-2 deletion mutants |
| CN103492411A (zh) * | 2011-02-10 | 2014-01-01 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| WO2019246404A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| TW202144391A (zh) * | 2020-03-19 | 2021-12-01 | 大陸商信達生物製藥(蘇州)有限公司 | 白介素2突變體及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| CN112105634B (zh) * | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| JP7864826B2 (ja) * | 2021-09-22 | 2026-05-25 | フォートビタ バイオロジクス(シンガポール)プライベート リミティド | インターロイキン2変異体およびその融合タンパク質 |
-
2021
- 2021-03-19 KR KR1020227034880A patent/KR20220155316A/ko active Pending
- 2021-03-19 TW TW110110014A patent/TWI790573B/zh active
- 2021-03-19 AU AU2021239225A patent/AU2021239225B2/en active Active
- 2021-03-19 CN CN202180021848.0A patent/CN115698052A/zh active Pending
- 2021-03-19 WO PCT/CN2021/081840 patent/WO2021185361A1/zh not_active Ceased
- 2021-03-19 CA CA3175717A patent/CA3175717A1/en active Pending
- 2021-03-19 JP JP2022556114A patent/JP7879043B2/ja active Active
- 2021-03-19 EP EP21771688.5A patent/EP4122952A4/en active Pending
- 2021-03-19 US US17/911,893 patent/US20230145766A1/en active Pending
-
2026
- 2026-01-08 JP JP2026001948A patent/JP2026081255A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002000A1 (en) * | 1989-08-02 | 1991-02-21 | Seragen, Inc. | Il-2 deletion mutants |
| CN103492411A (zh) * | 2011-02-10 | 2014-01-01 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| WO2019246404A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| TW202144391A (zh) * | 2020-03-19 | 2021-12-01 | 大陸商信達生物製藥(蘇州)有限公司 | 白介素2突變體及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4122952A1 (en) | 2023-01-25 |
| AU2021239225A1 (en) | 2022-10-13 |
| WO2021185361A1 (zh) | 2021-09-23 |
| CA3175717A1 (en) | 2021-09-23 |
| US20230145766A1 (en) | 2023-05-11 |
| JP7879043B2 (ja) | 2026-06-23 |
| KR20220155316A (ko) | 2022-11-22 |
| CN115698052A (zh) | 2023-02-03 |
| EP4122952A4 (en) | 2024-05-29 |
| JP2026081255A (ja) | 2026-05-18 |
| TW202144392A (zh) | 2021-12-01 |
| JP2023518434A (ja) | 2023-05-01 |
| AU2021239225B2 (en) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI834031B (zh) | 白介素2突變體及其用途 | |
| TWI791894B (zh) | 新型白介素2及其用途 | |
| TW202144392A (zh) | 白介素2突變體及其用途 | |
| CN112105634B (zh) | 新型白介素2及其用途 | |
| TW202320862A (zh) | 介白素2突變體以及其融合蛋白 | |
| CN114585377A (zh) | 表达嵌合蛋白的t细胞 | |
| CA3098765C (en) | Novel interleukin-2 and use thereof |